The Ebbs and Flows in the Development of Cholesterol‐Lowering Drugs: Prospects for the Future

E-ISSN： 1532-6535|96|1|64-73

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.96, Iss.1, 2014-07, pp. : 64-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cholesterol-lowering drugs and Alzheimer’’s disease

By Eckert Gunter P Müüller Walter E Wood W Gibson

Future Lipidology, Vol. 2, Iss. 4, 2007-08 ,pp. : 423-432

Future Medicine

Access to resources Recommend Favorite

Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review

Reviews on Recent Clinical Trials, Vol. 7, Iss. 2, 2012-05 ,pp. : 150-157

Bentham Science Publishers

Access to resources Recommend Favorite

Pleiotropic Effects and Cholesterol-Lowering Therapy

Cardiology, Vol. 112, Iss. 1, 2008-06 ,pp. : 4-12

Karger

Access to resources Recommend Favorite

Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

By Mikhailidis D. P. Sibbring G. C. Ballantyne C. M. Davies G. M. Catapano A. L.

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 2009-2026

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of cholesterol-lowering and antioxidant properties of sugar cane policosanols in hamsters and humans

By Kassis Amira N.

Applied Physiology, Nutrition, and Metabolism, Vol. 33, Iss. 3, 2008-06 ,pp. : 540-541

NRC Research Press

Access to resources Recommend Favorite